Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group (Q40739863)

From Wikidata

Jump to navigation Jump to search

scientific article published on January 1992

Language	Label	Description	Also known as
English	Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group	scientific article published on January 1992

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Alice K. Jacobs

object named as

A Jacobs

6

0 references

author name string

H H Gerhartz

1

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

R Marcus

2

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

A Delmer

3

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

H Zwierzina

4

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

T de Witte

5

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

G Visiani

7

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

D Fiere

8

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

P Sonneveld

9

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

B Labar

10

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

publication date

1 January 1992

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

20 Suppl 2

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

S116-23

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1007/BF01705030

21 January 2018

Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial

1 reference

https://api.crossref.org/works/10.1007/BF01705030

21 January 2018

Response of preleukemic syndromes to continuous infusion of low-dose cytarabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The preleukemic syndrome (hemopoietic dysplasia).

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Refractory dysmyelopoietic anemia and acute leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

On the value of intensive remission-induction chemotherapy in elderly patients of 65 years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recurrent spleen enlargement during cyclic granulocyte-macrophage colony-stimulating factor therapy for myelodysplastic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant gamma-interferon as first line therapy for high risk myelodysplastic syndromes. Italian MDS Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of low dose Ara-C in acute nonlymphoblastic leukaemias and atypical leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor: a preliminary report

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myelodysplastic syndromes: a scoring system with prognostic significance

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Loss of ras oncogene mutation in a myelodysplastic syndrome after low-dose cytarabine therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low dose Ara-C for patients with myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-3 and granulocyte-monocyte colony-stimulating factor receptors on human acute myelocytic leukemia cells and relationship to the proliferative response

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human recombinant granulocyte-macrophage colony-stimulating factor increases cell-to-cell adhesion and surface expression of adhesion-promoting surface glycoproteins on mature granulocytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo differentiation of leukaemic blasts and effect of low dose Ara-C in a marrow grafted patient with leukaemic relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low dose cytosine arabinoside (Ara C) in myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human GM-CSF: molecular cloning of the complementary DNA and purification of the natural and recombinant proteins

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peripheral acute leukemia: high peripheral but low-marrow blast count

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term alpha-interferon therapy in myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of interleukin 3 on cytosine arabinoside-mediated cytotoxicity of leukemic myeloblasts

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human granulocyte colony-stimulating factor repairs the abnormalities of neutrophils in patients with myelodysplastic syndromes and chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Patterns of acute myeloid leukemia colony growth in response to recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF)

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of Granulocyte Colony-Stimulating Factor after Intensive Induction Therapy in Relapsed or Refractory Acute Leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase I/II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human granulocyte-macrophage colony-stimulating factor and low-dose cytosine-arabinoside in the treatment of patients with myelodysplastic syndromes. A phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/1493935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF01705030

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40739863&oldid=2228523092"